Penile metastasis from colon cancer with BRAF (V600E) mutation treated with BRAF/MEK-targeted therapy plus cetuximab: A case report

一例BRAF(V600E)突变结肠癌阴茎转移患者接受BRAF/MEK靶向治疗联合西妥昔单抗治疗的病例报告

阅读:1

Abstract

BACKGROUND: The incidence of colon cancer has been progressively increasing over time, whereas penile metastasis of colon cancer has remained exceedingly uncommon. Since the prognosis for colon cancer with BRAF (V600E) mutation is relatively unfavorable, further exploration and investigation are still required to develop treatment strategies for such rare cases. CASE SUMMARY: About one year after surgery and chemotherapy, a 50-year-old patient with sigmoid colon cancer developed a mass at the base of the patient's penis, accompanied by severe tenderness and pain during urination. With disease progression, multiple metastatic nodules also emerged in other regions of the penis, including the coronal sulcus. The nodules located in the coronal sulcus were excised for histopathological examination. The histopathological findings revealed that the nodules were metastases originating from the sigmoid colon cancer, with a BRAF (V600E) mutation detected. This prompted a modification of the therapy regimen of cetuximab, dabrafenib and trametinib, which effectively held back the progression of penile metastasis in the patient. CONCLUSION: Combining the BRAF/MEK-targeted therapy with cetuximab demonstrates a favorable therapeutic response in BRAF (V600E)-mutated colon cancer with penile metastasis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。